Julian Baker’s Voyager Therapeutics VYGR Stock Holding History

Julian Baker’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-237,014	Closed	-$4.88M	–	124
2017 Q3	$4.88M	Buy	+237,014	New	+$2.67M	0.04%	78

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Julian Baker's VYGR Position: Q4 2017 in Review

Julian Baker sold out of Voyager Therapeutics (VYGR) in Q4 2017, closing a stake of 237,014 shares — an estimated $4.88M sold.

Julian Baker first reported a position in VYGR in Q3 2017 and held it in 1 quarter. The position peaked at $4.88M in Q3 2017. 98 funds tracked by Wall St. Rank hold VYGR as of Q4 2017.

Julian Baker reported no remaining Voyager Therapeutics position as of Q4 2017 after selling out during the quarter.
Julian Baker sold 237,014 Voyager Therapeutics shares in Q4 2017, an estimated $4.88M.
Julian Baker first reported a position in Voyager Therapeutics in Q3 2017 and held it in 1 quarter.
Julian Baker's Voyager Therapeutics position peaked at $4.88M in Q3 2017.
98 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2017.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.